Clinical evaluation of the effect of infliximab on spondyloarthropathy at baseline and week 12 in study populations I and II
| Variable | Study population I (n = 10) | Study population II (n = 20) | ||||
|---|---|---|---|---|---|---|
| Baseline | Week 12 | p Value* | Baseline | Week 12 | p Value* | |
| Results are expressed as median (range). | ||||||
| Global and peripheral joint assessments on a 100 mm visual analogue scale. | ||||||
| *p Values calculated using the paired Wilcoxon signed rank test. | ||||||
| ESR, erythrocyte sedimentation rate; VAS, visual analogue scale. | ||||||
| Patient pain (VAS) | 57 (14 to 97) | 20 (1 to 39) | 0.005 | 69 (14 to 100) | 16 (1 to 86) | <0.001 |
| Patient global (VAS) | 64 (17 to 98) | 12.5 (0 to 47) | 0.005 | 69 (17 to 100) | 15 (0 to 73) | <0.001 |
| Physician global (VAS) | 71 (59 to 89) | 17 (8 to 31) | 0.005 | 64 (35 to 89) | 15 (8 to 75) | <0.001 |
| ESR (mm/h) | 23.5 (11 to 101) | 6 (1 to 34) | 0.007 | 28 (11 to 101) | 7 (1 to 59) | <0.001 |
| C reactive protein (mg/dl) | 2.3 (0.96 to 7.42) | 0.26 (0 to 7.93) | 0.047 | 3.4 (1.0 to 29.0) | 0.3 (0 to 7.9) | 0.001 |
| Patient pain peripheral joints (VAS) | 55.5 (20 to 90) | 18 (4 to 40) | 0.007 | 64 (20 to 99) | 18 (0 to 84) | <0.001 |
| Duration of morning stiffness (min) | 235 (0 to 300) | 15 (0 to 90) | 0.008 | 133 (0 to 300) | 10 (1 to 90) | <0.001 |
| Tender joint count (n) | 10 (3 to 20) | 0.5 (0 to 6) | 0.007 | 10 (1 to 20) | 0 (0 to 6) | <0.001 |
| Swollen joint count (n) | 5.5 (2 to 24) | 0.5 (0 to 3) | 0.008 | 7 (0 to 24) | 1 (0 to 7) | <0.001 |